Citation

BibTex format

@article{Balkwill:2026:10.1038/s41568-026-00916-0,
author = {Balkwill, FR and Laumont, CM and Burdett, N and Le, Saux O and Garsed, DW and Grither, WR and Nijhuis, AM and Recouvreux, MS and Kang, Z and Zhang, R and Chiappinelli, KB and Lee, JS and Laniti, DD and McNeish, I and Ahmed, AA and Rottapel, R and Conejo-Garcia, JR and Odunsi, K and Pharoah, PDP and Zamarin, D and Ishak, CA and Fotopoulou, C and Buckanovich, RJ and Labidi-Galy, I and Brenton, JD and Lengyel, E and Cook, DP and George, SHL and Lheureux, S and Drapkin, R and Nephew, KP and Adams, S and Pathania, S and Nelson, BH and Färkkilä, A and Fuh, K and Neel, BG and Bowtell, DD},
doi = {10.1038/s41568-026-00916-0},
journal = {Nat Rev Cancer},
title = {Rethinking ovarian cancer III: the past decade and future directions.},
url = {http://dx.doi.org/10.1038/s41568-026-00916-0},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead.
AU  - Balkwill,FR
AU  - Laumont,CM
AU  - Burdett,N
AU  - Le,Saux O
AU  - Garsed,DW
AU  - Grither,WR
AU  - Nijhuis,AM
AU  - Recouvreux,MS
AU  - Kang,Z
AU  - Zhang,R
AU  - Chiappinelli,KB
AU  - Lee,JS
AU  - Laniti,DD
AU  - McNeish,I
AU  - Ahmed,AA
AU  - Rottapel,R
AU  - Conejo-Garcia,JR
AU  - Odunsi,K
AU  - Pharoah,PDP
AU  - Zamarin,D
AU  - Ishak,CA
AU  - Fotopoulou,C
AU  - Buckanovich,RJ
AU  - Labidi-Galy,I
AU  - Brenton,JD
AU  - Lengyel,E
AU  - Cook,DP
AU  - George,SHL
AU  - Lheureux,S
AU  - Drapkin,R
AU  - Nephew,KP
AU  - Adams,S
AU  - Pathania,S
AU  - Nelson,BH
AU  - Färkkilä,A
AU  - Fuh,K
AU  - Neel,BG
AU  - Bowtell,DD
DO  - 10.1038/s41568-026-00916-0
PY  - 2026///
TI  - Rethinking ovarian cancer III: the past decade and future directions.
T2  - Nat Rev Cancer
UR  - http://dx.doi.org/10.1038/s41568-026-00916-0
UR  - https://www.ncbi.nlm.nih.gov/pubmed/41975230
ER  -
Download